EP06.03-21 Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China

Dabrafenib plus trametinib combination treatment received approval and reimbursement for patients with serine/threonine protein kinase B-raf (BRAF) V600-mutant advanced non-small-cell lung cancers (NSCLCs) in China. Real-time polymerase chain reaction/next-generation sequencing (RT-PCR/NGS) are recommended tests to select patients for BRAF-targeted combination therapy. However, the accessibility of RT-PCR/NGS platform is relatively low. While immunohistochemistry (IHC) is a rapid, inexpensive assay that is available in most laboratories.